Abstract:Background This study aimed to establish and validate an accurate prognostic model, based on demographic and clinical parameters, for predicting the cancer-specific survival (CSS) of patients with poorly differentiated thyroid carcinoma (PDTC). Materials and methods Patients diagnosed with PDTC between 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Randomly split the data into training and validation sets. Kaplan–Meier analysis with the log-rank test was performed to compare the survival distribution among cases. Univariate and multivariate Cox proportional hazards regression analyses were used to identify independent prognostic factors, which were subsequently utilized to construct a nomogram for predicting the 5- and 10-year cancer-specific survival of patients with PDTC. The discriminative ability and calibration of the nomogram model were assessed using the concordance index and calibration plots, respectively. In addition, we performed a decision curve analysis to assess the clinical value of the nomogram. Simultaneously, we compared the predictive performance of the nomogram model against that of the American Joint Committee on Cancer (AJCC) T-, N-, M-stage. Results A total of 970 eligible patients were randomly assigned to either a training cohort (n = 679) or a validation cohort (n = 291). The Kaplan–Meier analysis revealed that there were no significant differences in cumulative survival based on the race, radiation, and marital status of patients. The stepwise Cox regression model showed that the model was optimal when the following five variables were included: age, tumor size, T-, N-, and M-stage. A nomogram was developed as a graphical representation of the model and exhibited good calibration and discriminative ability in the study. Compared to the T-, N-, and M-stage, the C-index of nomogram (training group: 0.807, validation group: 0.802), the areas under the receiver operating characteristic curve of the training set (5-year AUC: 0.843, 10-year AUC:0.834) and the validation set (5-year AUC:0.878, 10-year AUC:0.811), and the calibration plots of this model all exhibited better performance. At last, compared with T-, N-, and M-stage, the decision curve analysis indicated that the nomogram had excellent clinical net benefit. Conclusions The nomogram developed by us can accurately predict the CSS of PDTC patients. It can help clinicians determine appropriate treatment strategies for poorly differentiated thyroid carcinoma patients.

Development and Validation of a Nomogram for Predicting Survival in Patients with Testicular Germ Cell Tumors

Establishment and Validation of an Individualized Nomogram for Survival Prediction of Primary Mediastinal Germ Cell Tumors Based on the SEER Database.

Prognostic Nomograms for Patients with Metastatic Gastric Cancer: A Large Population-Based Cohort Study and External Validation

Clinical features and prognostic factors in patients diagnosed with lymphovascular invasion of testicular germ-cell tumors: Analysis based on the SEER database

Development and Validation of a Prognostic Nomogram to Predict Overall Survival and Cancer-Specific Survival for Patients with Anaplastic Thyroid Carcinoma

Development and Validation of Nomograms for Predicting Survival in Patients with Non-Metastatic Colorectal Cancer

Develop and validate nomogram to predict cancer-specific survival for patients with testicular yolk sac tumors

Development and Validation of a Nomogram for Predicting Survival in Patients with Resected Non-Small-cell Lung Cancer.

Competing risk nomogram predicting cause-specific mortality in older patients with testicular germ cell tumors

Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients with Typical Lung Carcinoid Tumors.

Development and validation of a nomogram for predicting survival in gastric signet ring cell carcinoma patients treated with radiotherapy

Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis

Development and Validation of Nomograms for Predicting Overall and Cancer-Specific Survival in Young Patients with Non-Small Cell Lung Cancer

Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort

Development and external validation of nomograms for predicting individual survival in patients with ovarian clear cell carcinoma

Developing and validating a nomogram for penile cancer survival: A comprehensive study based on SEER and Chinese data

Development and Validation of a Nomogram Model for Cancer-Specific Survival of Patients with Poorly Differentiated Thyroid Carcinoma: A SEER Database Analysis

Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study

Development and External Validation of Nomograms for Predicting Disease-Free Survival and Overall Survival in Patients with cT1-ccRCC After Partial Nephrectomy: A Multicenter Retrospective Study

Development and validation of a nomogram in survival prediction among advanced breast cancer patients

Development and Validation of a Nomogram for Predicting Survival in Intermediate- and High-Risk Neuroblastoma of the Children's Oncology Group Risk Stratification.